Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood|March 31, 2025
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AMLZhe Wang, Anna Skwarska, Gowri Poigaialwar, et al.
Blood|April 3, 2025
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML OutcomesPatrick K Reville, Bofei Wang, Jennifer Marvin-Peek, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2026
Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid LeukemiaMahesh Swaminathan, Hussein A Abbas, Michael Roth, et al.
Journal of Hematology & Oncology|November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
Haematologica|December 12, 2024
Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasmsJayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative AnalysisNaval Daver, Jayastu Senapati, Hagop M Kantarjian, et al.
Leukemia|March 12, 2026
Immunophenotypic changes following menin inhibition in acute myeloid leukemiaSanam Loghavi, Aziz Farhat, Trevor J Jamison, et al.
American Journal of Hematology|September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatmentCurtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Pageof 10